-- The announcement follows recent advancements in epilepsy management with Argent BioPharma’s CannEpil drug, for which the company has secured a position within the UK’s National Health Service (NHS). Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) has plans to expand to larger markets in Europe and North America and will be filing an IND application with the U.S. Food and Drug Administration for a 2030 market launch.
For more information, please visit https://argentbiopharma.com/
According to an article in Frontiers in Neurology, refractory epilepsy, also known as drug-resistant epilepsy (DRE), affects 30% of generalised seizure epilepsy patients, an equivalent of 15 million individuals around the world. These patients do not respond to conventional medications, underscoring the need for an alternative biopharmaceutical approach and leading Argent BioPharma to develop CannEpil.
Following numerous successful clinical trials, CannEpil has been accepted by the Irish Health Product Regulatory Authority and is currently in use by epilepsy patients in the UK and Ireland. The product is already generating revenue under early access schemes in both countries, with treatment estimates per patient per annum currently valued at £7000.
In addition to CannEpil, Argent BioPharma’s other revenue-generating assets include CimetrA, an anti-inflammatory drug for acute lung injury and acute respiratory distress syndrome that is slated for market launch in 2031. Also notable is its CogniCann, a novel therapy for dementia and Alzheimer’s with plans for a 2033 launch. The company owns two EU-GMP-certified manufacturing sites and is capable of producing over six million units of all of its products annually.
To learn more about the company’s financial standing, please visit https://argentbiopharma.com/financial-reports/
About Argent BioPharma
Argent BioPharma takes an integrated approach to biopharmaceuticals, combining nanotechnology with multidisciplinary research methods. The company aims to be a pioneer in multi-targeted drug therapies and nanoscale delivery designed to enhance efficacy and reduce side effects.
“We aspire to become a leading biopharmaceutical company recognised globally for its innovative treatments that address unmet medical needs, particularly in the central nervous system and immune-related diseases,” explains a spokesperson for the company. "Our goal is to transform patient outcomes by providing effective therapies for conditions with limited or no treatment options."
Interested parties can learn more about Argent BioPharma’s research by visiting https://argentbiopharma.com/research_reports/
Contact Info:
Name: Corey Pearce
Email: Send Email
Organization: Argent Biopharma
Address: 21 Eccleston Place 25 Eccleston Place, London, England SW1W 9NF, United Kingdom
Website: https://argentbiopharma.com/
Release ID: 89153447